Rx License-Rx
← Back to AI Screener Open university listing

LicenseRx asset brief

Real-Time RT-PCR Detection of Rickettsia species -- PanR6/Total Nucleic Acid Assay with High Sensitivity and Specificity

National Institutes of Health Preclinical Cell/Gene Therapy
Probability of Success

22% · grade C · Medium data confidence

Model PoS 22% (grade C, medium data confidence). Strongest signals: Data maturity, Competitive whitespace. Biggest drag: IP position.

Data maturity (22%) 58

Preclinical; clinical reference.

IP position (16%) 30

Protection lapsed or abandoned -- verify freedom to operate.

Modality feasibility (14%) 55

Cell/gene therapy -- high upside, heavy manufacturing and regulatory load.

Indication pull (14%) 70

Infectious Disease -- active buyer appetite.

Competitive whitespace (12%) 86

Under-served segment; multi-modal differentiation.

Translational evidence (12%) 54

Public evidence mentions: clinical.

Licensing readiness (10%) 94

Listed as available for licensing; established tech-transfer office; 1 public source link(s).

Unlock the full strategic deep dive

Cost to the next milestone, decisive data, relevant articles, and the partner-ready development plan for this asset.

View Operator access See what's included →